Vicore Pharma recruits the first patient in the phase 2 proof-of-concept study in idiopathic pulmonary fibrosis

Vicore Pharma recruits the first patient in the phase 2 proof-of-concept study in idiopathic pulmonary fibrosis. (Credit: PublicDomainPictures from Pixabay)